Mizuho Upgrades Outlook: Harmony’s Wakix Now Protected Until 2030
Harmony Biosciences wins key patent lawsuit, protecting Wakix from generics until ~2030; analyst stays positive with $50 target.
/ 60 items
#XY News-Driven Stocks↓
Agios Pharma Shares Crash as Novo Nordisk Posts Strong Phase 3 Sickle Cell Results
Novo Nordisk’s new pill cuts sickle cell pain crises, boosting outcomes and sending Agios Pharma shares down after strong trial results.
Lilly Buys Kelonia for Up to $7 Billion to Make CAR-T Cancer Therapy Simple and Fast
Eli Lilly buys Kelonia to develop a simpler, one-shot cancer therapy that reprograms immune cells directly inside the body.
Lilly’s Foundayo Pill Launches Strong: 1,400 Prescriptions in Week 1
Eli Lilly’s new GLP-1 pill shows strong early demand, big weight loss benefits, and promising heart & diabetes results.
Trump to Launch Federal Research on Psychedelic Drug Ibogaine for PTSD
Trump plans to boost research on ibogaine for PTSD in veterans, despite safety concerns and its illegal status in the US.
RFK Jr. Boosts Hims & Hers: FDA to Ease Restrictions on Popular Peptides
Hims & Hers Health jumps as FDA may ease rules on peptides, but experts warn they may be unsafe and lack proper testing.